Extended Data Fig. 4: Anti-tumor activity of MRTX1133 in KRASG12D-mutant xenografts of colon and pancreatic cancer histology in human pre-clinical models.
From: Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor
(a) MRTX1133 was administered i.p. BID at 30 mg/kg to mice bearing the cell line xenograft (n = 5/group) or PDX model (n = 4/group) indicated. The % change from baseline control was calculated at Day 14 for most models. Statistical significance is shown in Supplementary Table 2. (b) Pearson correlation between in vivo efficacy and PTEN expression in cell line xenografts and PDX models. Data shown with 95% confidence interval of the estimate around the correlation line, with standard error (predicted value + /− 1.96*se), no adjustments for multiple comparisons. (c) Pearson correlation between in vivo efficacy and CDKN2A expression in cell line xenografts and PDX models. Data shown as in Panel B.
